Testagen
Tetrapeptide directed at the testicular and reproductive axis, taken in short courses by men hoping to support endogenous testosterone and spermatogenesis - with essentially no evidence that it does either.
Also known as Lys-Glu-Asp-Gly, KEDG, testis Cytogen, Testagen tetrapeptide, Testagen
Animal data only — Rodent or other animal studies. Dose translation to humans is genuinely uncertain.
The evidence is aged-rodent reproductive tissue work from Khavinson's institute. There is no published human hormone or fertility data at all. Of all the Cytogens, this is the one where the gap between marketing claims and evidence is widest, because it competes directly with drugs that demonstrably work.
How it works
Testagen is Lys-Glu-Asp-Gly, differing from Epitalon only in its first residue and from Pancragen only in its last. Khavinson's group describes restoration of spermatogenic activity and normalisation of gonadotropin response in aged rodents, framed through the standard chromatin de-repression model. There is no published human hormone panel data - no LH, FSH or total testosterone response has ever been shown in a person. The marketing overlap with actual HPG-axis drugs like gonadorelin and hCG is where this compound becomes misleading: it has none of their demonstrated endocrine activity.
Targets: Testicular tissue, Spermatogenesis, Hypothalamic-pituitary-gonadal axis
Dosing
| Protocol | Dose | Frequency | Route |
|---|---|---|---|
| Oral capsule courseBefore food. | 1 mg – 2 mg | once daily for 20 to 30 days | oral |
| Research-market injectable courseAny time of day. | 1 mg – 2 mg | once daily for 10 to 20 days | subcutaneous |
- · Capsules are the primary format.
- · Standard vial-market protocol from a 20 mg vial.
Cycling
A month of capsules or ten to twenty days injectable, two to three courses per year.
Pharmacology
- Half-life
- Not measured; a free tetrapeptide clears from plasma within minutes.
- Onset
- Nothing acute. Spermatogenesis runs on a roughly 74-day cycle, so any genuine effect on sperm parameters could not appear in under three months.
- Routes
- oral, subcutaneous
- Molecule
- Synthetic tetrapeptide
- Sequence length
- 4 amino acids
- Molecular weight
- 447.4 Da
Handling
- Diluent
- Bacteriostatic water
- Typical mix
- 2 or 3 mL
- Vial sizes
- 20 mg
- Lyophilised
- Room temperature short term; fridge or freezer long term.
- Reconstituted
- Refrigerated, use within about 30 days.
- Light sensitive
- Yes — keep it out of the light
Mixing
20 mg in 2 mL gives 10 mg/mL; 1 mg is 10 units on a U-100 syringe.
Side effects
- commonInjection-site irritation— Transient.
- commonNo consistent systemic side effects reported— Thin exposure data.
Do not use if
- Do not use this as a post-cycle or HPG-axis restart agent - it has no demonstrated gonadotropic activity and using it instead of hCG or gonadorelin wastes recovery time you cannot get back.
- Hormone-sensitive malignancy, particularly prostate cancer.
- Pregnancy - not applicable to the target user, but the compound has no reproductive safety data.
Combining it
- redundanttestoluten — Testoluten is the testis Cytomax extract; same claimed target.
- cautionhcg — hCG has real, measurable gonadotropic activity; running Testagen alongside it just makes attribution impossible.
- redundantgonadorelin — Gonadorelin actually drives LH and FSH release. Testagen does not.
What to monitor
- · A full male hormone panel - total and free testosterone, LH, FSH, SHBG, oestradiol - before and about six weeks after a course, because that is the only way to catch the fact that nothing changed.
- · Semen analysis at baseline and at three months if fertility is the goal.
Legal status
Not approved for human use in the US, UK or EU; sold as a research chemical or as a supplement capsule in Russia and Eastern Europe.
References
- Khavinson & Malinin, Gerontological Aspects of Genome Peptide Regulation (Karger monograph) (review)
- Anisimov & Khavinson, peptide bioregulation of aging: results and prospects (Biogerontology) (review)
Mechanism in depth
Read the actual literature on Testagen and the first thing you notice is that almost none of it is about testes. Fedoreyeva and Vanyushin used it as one of their three model peptides for the nuclear-penetration study, showing that fluorescein-labelled Lys-Glu-Asp-Gly enters HeLa cytoplasm, nucleus and nucleolus and binds deoxyribooligonucleotides with a preference for CAG-containing sequences. That is a chemistry result, not an endocrine one. The functional in vivo work is Kuznik and Pateyuk's series in neonatally hypophysectomised chickens and old hens, where KEDG and Epitalon were given and the endpoints were thyroid structure and hormonal activity, thymus morphology, immunity and haemostasis. Thyroid. Thymus. Not gonads. Across three papers spanning 2008 to 2013 the reported effects are on thyroid morphology and hormone output in birds whose pituitary had been removed. There is a coherent reading of that - these peptides may act on pituitary-dependent tissues in general - but it is not the reading printed on the vial. What I could not find, anywhere, is a study measuring testosterone, LH, FSH, sperm count or motility in any species after Testagen administration. Not in humans, not in rodents, not in birds. The compound is sold into the men's hormone market on a name and a naming convention, and the gap between what the label implies and what the literature contains is the widest in this entire class.
What usually goes wrong
This is the compound in the class most likely to cost someone something real. A man with symptomatic hypogonadism, or a man twelve weeks off cycle with a suppressed axis, runs Testagen courses for six months because it is marketed as a testicular peptide. Nothing happens, because there is no published evidence it does anything to the gonadal axis in any species. Meanwhile the actual window for post-cycle intervention closes, or a pituitary adenoma or a haemochromatosis or a sleep apnoea goes undiagnosed. The second problem is that vendors describe it in language borrowed from gonadorelin and hCG, which have unambiguous, measurable endocrine effects. That borrowing is the misleading part, not the peptide itself. Third, the same class-wide problems: no pharmacokinetics, no human data, an unresolved dosing gap.
Bloodwork worth running
| Marker | When | Why it matters |
|---|---|---|
| Total testosterone, free testosterone, SHBG, LH, FSH and oestradiol | Baseline on two morning draws, then repeat six to eight weeks after the course. | Not because Testagen is expected to move them, but because a full panel before and after is the only way to establish that it did not - and that is genuinely valuable information for someone about to spend a year on this instead of on something that works. Draw testosterone between 8 and 10 in the morning, fasted, on two separate days.Act if: Total testosterone consistently below about 300 ng/dL with symptoms means genuine hypogonadism, and the workup is LH and FSH to separate primary from secondary, then a prolactin and a pituitary assessment if secondary. That is a medical pathway with effective treatments. Running peptide courses instead of following it wastes years. |
| TSH, free T4 and free T3 | Baseline and six weeks post-course. | This is the panel the actual published Testagen literature would predict something from, since the in vivo work is thyroid work in birds. If anything endocrine moves on this compound, thyroid is the more evidence-consistent place to look than testes.Act if: No human data supports an expected change. Any shift in TSH deserves its own investigation rather than attribution to the peptide. |
| Semen analysis | Baseline and at three to four months, with two days to seven days of abstinence held constant between samples. | If fertility is the goal, this is the endpoint. Spermatogenesis takes about 74 days, so anything measured before three months is meaningless.Act if: Abnormal parameters mean a urology referral and a proper workup, including a scrotal ultrasound and karyotype where indicated. Male factor infertility has real treatments and a peptide with no fertility data is not one of them. |
Pharmacokinetics
- Metabolism
- Aminopeptidase cleavage to lysine, glutamate, aspartate and glycine.
- Elimination
- Renal filtration of fragments.
Receptor targets
- Nuclear DNA, CAG-containing sequences — Stern-Volmer quenching constants only; no molar Kd
Testagen was one of three peptides shown to reach the nucleus and nucleolus in HeLa cells and to bind deoxyribooligonucleotides with sequence and methylation-state discrimination.
- Thyroid gland structure and hormone output
Reported changes in thyroid morphology and hormonal activity in neonatally hypophysectomised chickens and old hens - the most consistent in vivo endocrine finding for this peptide, and it is thyroid rather than gonadal.
- Thymus morphology
Reported effects on thymic structure in hypophysectomised young and old birds.
- Testicular tissue, spermatogenesis, LH/FSH/testosterone — None published
I could not verify a single study measuring any gonadal or gonadotropin endpoint after Testagen administration in any species. The reproductive claims are not supported by retrievable primary literature.
What to expect, and when
Nothing acute and, on the available evidence, nothing at all. Days one to twenty: injection-site irritation only. Six to eight weeks: the earliest a hormone panel could reflect a change in Leydig cell output, and the honest expected result is no change. Three months: spermatogenesis runs on roughly a 74-day cycle, so this is the earliest a semen analysis could show anything, and again there is no evidence to predict a change. If you are going to run this, run the panels, because a clean negative result at three months is the most useful thing this compound can give you.
Stacking and comparisons
There is no rational stack for this compound because there is no demonstrated activity to build around. Testagen plus Testoluten is duplication. The stacks that matter are the ones people abandon in favour of it: if you are trying to restart an HPG axis after a cycle, hCG and a SERM or gonadorelin have measurable, published gonadotropic effects and Testagen has none. If your testosterone is genuinely low, the pathway is a workup and then either treating the cause or replacement. Using Testagen alongside hCG makes attribution impossible and adds cost; using it instead of hCG loses recovery time that is genuinely hard to get back.
Against hCG: hCG is an LH analogue that directly stimulates Leydig cells and raises intratesticular testosterone measurably within days. Against gonadorelin: a GnRH analogue that drives pituitary LH and FSH release. Against enclomiphene or clomiphene: SERMs with documented effects on LH, FSH and total testosterone in randomised human studies. Testagen has none of that - not a single published gonadotropin or androgen measurement. Against the rest of the Cytogen series: Testagen has good chemistry papers, because it was chosen as a model peptide for the DNA-binding work, and no functional evidence for its named indication at all. That combination - well-characterised molecule, entirely absent evidence for the marketed use - is unusual and worth stating plainly.
Rough cost
$35–$110/month. One 20 mg vial per injectable course, or a month of capsules. Indicative pricing, not verified against vendor listings in this session.
Genuinely uncertain
- I could not verify a single study measuring testosterone, LH, FSH, spermatogenesis or any other gonadal endpoint after Testagen administration in any species.
- The verified in vivo endocrine work is on thyroid and thymus in hypophysectomised birds, which is a different claim entirely.
- No pharmacokinetic data of any kind by any route.
- No human data of any kind.
- Whether the avian hypophysectomy findings generalise to intact mammals is completely unknown.
- Oral absorption of the intact tetrapeptide has never been demonstrated.
- The microgram-versus-milligram dosing gap between the source literature and the vial market applies here as across the class.
- Cost figures are indicative estimates and were not verified against live vendor listings in this session.
Papers
- Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF, Biochemistry (Moscow), 2011 · PMID 22117547
Confirms the Lys-Glu-Asp-Gly sequence and shows the peptide reaching the nucleus with sequence-selective DNA binding. The strongest paper naming Testagen, and it is chemistry, not endocrinology.
- Effect of tetrapeptides Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly on the structure and function of the thyroid gland in neonatally hypophysectomized chickens Kuznik BI, Pateyuk AV, Rusaeva NS, et al., Bulletin of Experimental Biology and Medicine, 2008 · PMID 19024016
The in vivo endocrine work on this peptide is about the thyroid, not the testes. Worth reading purely to see how far the label has drifted from the data.
- Effects of peptides Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly on hormonal activity and structure of the thyroid gland in hypophysectomized young chickens and old hens Kuznik BI, Pateyuk AV, Rusaeva NS, et al., Bulletin of Experimental Biology and Medicine, 2011 · PMID 22268052
The follow-up in old hens, again thyroid rather than gonadal.
- Effect of peptides Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly on the morphology of the thymus in hypophysectomized young and old birds Pateyk AV, Baranchugova LM, Rusaeva NS, et al., Bulletin of Experimental Biology and Medicine, 2013 · PMID 23658898
Thymic morphology in the same avian hypophysectomy model.